Trial Profile

Double-blind, randomized, placebo-controlled study of Leriglitazone in pediatric Rett Syndrome - MT-2-04

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Leriglitazone (Primary)
Indications Rett syndrome
Focus Adverse reactions
Acronyms TREE
Sponsors Minoryx Therapeutics

Most Recent Events

14 Mar 2025 New trial record
04 Mar 2025 According to Minoryx Therapeutics media release, The results from the TREE study are expected during the first half of 2026 when all patients have concluded 36 weeks of treatment and 4 weeks of follow-up.
04 Mar 2025 According to Minoryx Therapeutics media release, company announces that the first patient in the TREE study has been dosed with leriglitazone.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com